| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX6 |
| Uniprot No | Q7RTT6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188 aa |
| 活性数据 | MNGDDAFAKR PRDDAKASEK RSKAFDDIAK YFSKEEWEKM KFSEKISCVH MKRKYEAMTK LGFNVTLSLF MRNKRATDSQ RNDSDNDRNR GNEVERPQMT FGRLQRIIPK IMPEKPAEEG SDSKGVPEAS GPQNDGKKLC PPGKASSSEK IHERSGPKRG KHAWTHRLRE RKQLVIYEEI SDPEEDDK |
| 分子量 | 21.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SSX6蛋白的3篇参考文献示例(注：以下内容为模拟生成，非真实文献，仅供格式参考)：
1. **标题**：*Cloning and Expression of Recombinant Human SSX6 Protein in E. coli for Antigenic Studies*
**作者**：Zhang L, et al.
**摘要**：报道了通过大肠杆菌表达系统高效克隆和纯化重组人SSX6蛋白，并验证其抗原性，为开发基于SSX6的癌症免疫诊断试剂奠定基础。
2. **标题**：*SSX6 as a Novel Cancer-Testis Antigen: Immunogenicity Analysis in Melanoma Patients*
**作者**：Müller F, et al.
**摘要**：研究证实SSX6在黑色素瘤中异常表达，重组SSX6蛋白可诱导患者外周血T细胞特异性免疫应答，提示其作为肿瘤疫苗靶标的潜力。
3. **标题**：*Structural Characterization of SSX6 Protein and Its Interaction with Histone Deacetylases*
**作者**：Kimura T, et al.
**摘要**：通过核磁共振解析重组SSX6蛋白的晶体结构，揭示其与组蛋白去乙酰化酶(HDAC)的相互作用，探讨其在表观遗传调控中的潜在功能。
如需真实文献，建议通过PubMed或Web of Science等数据库检索关键词“SSX6 protein recombinant”或“SSX6 cancer antigen”获取最新研究。
**Background of Recombinant Human SSX6 Protein**
The SSX6 protein, a member of the SSX (Synovial Sarcoma X breakpoint) family, is encoded by the *SSX6* gene located on human chromosome X. This family comprises nine paralogs (*SSX1-9*), initially identified for their role in synovial sarcomas via fusion with *SS18* (e.g., SS18-SSX), though SSX6 itself is not a common fusion partner. SSX proteins contain conserved domains, including an N-terminal KRAB-like transcriptional repression domain and a C-terminal divergent region implicated in protein interactions.
SSX6 is classified as a cancer-testis (CT) antigen due to its restricted expression in immune-privileged germline tissues (e.g., testis) and aberrant reactivation in various cancers, such as melanoma, lung, and breast cancers. This tumor-specific expression makes it a potential target for immunotherapy, including vaccines or adoptive T-cell therapies. Recombinant SSX6 protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), retains immunogenic epitopes, enabling its use in serological profiling, antibody production, and T-cell response studies.
Functionally, SSX6 is hypothesized to modulate transcriptional regulation or chromatin remodeling, though its precise mechanisms remain under investigation. Research on recombinant SSX6 aids in deciphering its role in oncogenesis and its utility as a biomarker or therapeutic target in precision oncology.
×
